AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
27 September 2022 - 9:00PM
Business Wire
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene
therapy company working to free people from a lifetime of genetic
disease, today announced that it will present new preclinical data
on novel assays used to evaluate lentiviral vector safety at the
29th Annual Congress of the European Society of Gene & Cell
Therapy (ESGCT), Oct. 11-14, 2022 in Edinburgh, Scotland.
Using IVIM/SAGA as screening tools during lentiviral vector
lead selection for detection of clinically translatable insertional
transformational risk Thursday, Oct. 13, 2022, 5:30 PM BST
(Poster session II)
Holly Horton, Ph.D., senior director Toxicology &
Preclinical Development at AVROBIO, will present data on AVROBIO’s
novel preclinical assays used to evaluate lentiviral vectors for
potential genotoxic or mutagenic behavior to inform vector
selection before initiating clinical programs.
The full program is available online at the ESGCT website.
About AVROBIO Our vision is to bring personalized gene
therapy to the world. We target the root cause of genetic disease
by introducing a functional copy of the affected gene into
patients’ own hematopoietic stem cells (HSCs), with the goal to
durably express the therapeutic protein throughout the body,
including the central nervous system. Our first-in-class pipeline
includes clinical programs for cystinosis and Gaucher disease type
1, as well as preclinical programs for Gaucher disease type 3,
Hunter syndrome and Pompe disease. Our proprietary plato® gene
therapy platform is designed to be scaled to support late-stage
clinical development and commercialization globally. We are
headquartered in Cambridge, Mass. For additional information, visit
avrobio.com, and follow us on Twitter and LinkedIn.
Forward-Looking Statements This press release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements may be identified by words and
phrases such as “aims,” “anticipates,” “believes,” “could,”
“designed to,” “estimates,” “expects,” “forecasts,” “goal,”
“intends,” “may,” “plans,” “possible,” “potential,” “seeks,”
“will,” and variations of these words and phrases or similar
expressions that are intended to identify forward-looking
statements. These forward-looking statements include, without
limitation, statements regarding our business strategy for and the
potential therapeutic benefits of our preclinical and clinical
product candidates, statements regarding the expectations or
activities of our collaborators including timing of clinical trial
initiation and dosing of patients, the design, commencement,
enrollment and timing of planned clinical trials, preclinical or
clinical trial results, product approvals and regulatory pathways,
our plans and expectations with respect to interactions with
regulatory agencies, anticipated benefits of our gene therapy
platform including potential impact on our commercialization
activities, timing and likelihood of success, the expected benefits
and results of our implementation of the plato platform in our
clinical trials and gene therapy programs, and the expected safety
profile of our preclinical and investigational gene therapies. Any
such statements in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Results in preclinical or early-stage clinical trials may not be
indicative of results from later stage or larger scale clinical
trials and do not ensure regulatory approval. You should not place
undue reliance on these statements, or the scientific data
presented.
Any forward-looking statements in this press release are based
on AVROBIO’s current expectations, estimates and projections about
our industry as well as management’s current beliefs and
expectations of future events only as of today and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that any
one or more of AVROBIO’s product candidates will not be
successfully developed or commercialized, the risk of cessation or
delay of any ongoing or planned clinical trials of AVROBIO or our
collaborators, the risk that AVROBIO may not successfully recruit
or enroll a sufficient number of patients for our clinical trials,
the risk that AVROBIO may not realize the intended benefits of our
gene therapy platform, including the features of our plato®
platform, the risk that our product candidates or procedures in
connection with the administration thereof will not have the safety
or efficacy profile that we anticipate, the risk that prior
results, such as signals of safety, activity or durability of
effect, observed from preclinical or clinical trials, will not be
replicated or will not continue in ongoing or future studies or
trials involving AVROBIO’s product candidates, the risk that we
will be unable to obtain and maintain regulatory approval for our
product candidates, the risk that the size and growth potential of
the market for our product candidates will not materialize as
expected, risks associated with our dependence on third-party
suppliers and manufacturers, risks regarding the accuracy of our
estimates of expenses and future revenue, risks relating to our
capital requirements and needs for additional financing, risks
relating to clinical trial and business interruptions resulting
from the COVID-19 outbreak or similar public health crises,
including that such interruptions may materially delay our
enrollment and development timelines and/or increase our
development costs or that data collection efforts may be impaired
or otherwise impacted by such crises, and risks relating to our
ability to obtain and maintain intellectual property protection for
our product candidates. For a discussion of these and other risks
and uncertainties, and other important factors, any of which could
cause AVROBIO’s actual results to differ materially and adversely
from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in AVROBIO’s most recent Annual or
Quarterly Report, as well as discussions of potential risks,
uncertainties and other important factors in AVROBIO’s subsequent
filings with the Securities and Exchange Commission. AVROBIO
explicitly disclaims any obligation to update any forward-looking
statements except to the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220927005434/en/
Investors: Christopher F. Brinzey Westwicke, an ICR
Company 339-970-2843 chris.brinzey@westwicke.com Media: Kit
Rodophele Ten Bridge Communications 617-999-9620
krodophele@tenbridgecommunications.com
AVROBIO (NASDAQ:AVRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AVROBIO (NASDAQ:AVRO)
Historical Stock Chart
From Apr 2023 to Apr 2024